Monitoring of occupational exposure to cytostatic anticancer agents.
about
Hazardous anticancer drugs in health care: environmental exposure assessmentOccupational exposure to chemotherapy of pharmacy personnel at a single centreAir samples versus biomarkers for epidemiologyA study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project.Occupational exposure to cytotoxic drugs in two UK oncology wards.Human effect monitoring in cases of occupational exposure to antineoplastic drugs: a method comparisonCancer prevention and therapy: strategies and problems.Occupational exposure to anti-cancer drugs: A review of effects of new technology.A review of surface wipe sampling compared to biologic monitoring for occupational exposure to antineoplastic drugs.Epirubicin permeation of personal protective equipment can induce apoptosis in keratinocytes.Development of a new method for sampling and monitoring oncology staff exposed to cyclophosphamide drug.Current challenges in European oncology pharmacy practice.Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients.Human papillomavirus type 16-immortalized endocervical cells selected for resistance to cisplatin are malignantly transformed and have a multidrug resistance phenotype.Large-cell neuroendocrine cancer of the colon following rituximab-based lymphoma treatment.Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry.Exposure of family members to antineoplastic drugs via excreta of treated cancer patients.Protective effect of lipoic acid on micronuclei induction by cyclophosphamide.Highly sensitive high-performance liquid chromatography/selective reaction monitoring mass spectrometry method for the determination of cyclophosphamide and ifosfamide in urine of health care workers exposed to antineoplastic agents.Chromosomal damage in peripheral blood lymphocytes from nurses occupationally exposed to chemicals.Mutagenic activity of overnight urine from healthy non-smoking subjects.Immunotoxicity monitoring of hospital staff occupationally exposed to cytostatic drugs.Evaluation of ultraviolet irradiation efficacy in an automated system for the aseptic compounding using challenge test.Assessment of primary, oxidative and excision repaired DNA damage in hospital personnel handling antineoplastic drugs.Investigating genetic damage in workers occupationally exposed to methotrexate using three genetic end-points.
P2860
Q23922583-E9780BCE-1925-42AF-9D1B-2BA67597A93AQ28392801-E62A934C-739D-460C-9749-76F95BE8E220Q28393946-14358083-8EEC-427B-AB24-BC05D917C410Q33857689-22728BCE-62A6-4468-AD4F-C1AD73AFD79DQ35496593-848B00EF-256E-4E5A-A590-76ECCEC5D04EQ35560680-496C0D65-3AE6-46AA-8219-DDD8BC2B05E1Q35594641-48E860E5-54BD-4838-AE34-F5E3A858C258Q38131440-71C22310-AE21-403A-BA76-6899D6D38794Q38817214-F9A980D1-3001-43B1-8683-4C47C13055DAQ39351905-F808216A-F1A2-44A8-8BC1-7AD25F2C6AEAQ39898348-9F36B349-FF6A-4B1F-B2C7-FC4B5F94EAD3Q39918562-460B58D3-128E-4712-BDBE-DC746DEDDB41Q40202141-E4CA00A8-E278-4C8C-AB21-2FCCA9B5C3CCQ40859204-BF2877D7-3D3D-4D47-8769-FC60F9D34811Q40949926-41DF5DD8-56C0-46DA-AAEA-A8569F307084Q43363555-BFEE8677-137E-4911-B6E9-BC833BDC4537Q44802357-0FA7BE50-C403-47F4-A17D-84B6A15CFCA1Q46641438-B84A6502-E562-4E51-9348-63CB0D3D8038Q46688685-0282B7DD-837B-4195-9DF9-62B54C4EC8F4Q47945060-83B70339-0FDA-4C2F-A9C6-F606843C9A97Q50073692-9D525856-E726-4B96-91BC-75B59B76CDE2Q50786905-B7A6D6A4-27F8-42C3-A347-DE025E85360EQ50872602-21479C53-6F35-43B3-981A-CA1D4C3DAB4AQ53163487-7CC3E514-9A1F-43A7-82CB-C71ED6A7AD7BQ53665227-8D55F1EE-2569-4064-9C89-40B6611E797D
P2860
Monitoring of occupational exposure to cytostatic anticancer agents.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Monitoring of occupational exposure to cytostatic anticancer agents.
@en
type
label
Monitoring of occupational exposure to cytostatic anticancer agents.
@en
prefLabel
Monitoring of occupational exposure to cytostatic anticancer agents.
@en
P1433
P1476
Monitoring of occupational exposure to cytostatic anticancer agents
@en
P2093
P304
P356
10.1016/0027-5107(96)00031-0
P407
P577
1996-08-01T00:00:00Z